Copyright Reports & Markets. All rights reserved.

Global Hyperimmune Globulin Injection Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Hyperimmune Globulin Injection Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Hepatitis B Immuneglobulins
    • 1.3.3 Rabies Immuneglobulins
    • 1.3.4 Tetanus Toxin Immuneglobulins
    • 1.3.5 Rho(D) Immune Globulin
    • 1.3.6 Cytomegalovirus Immune Globulin
    • 1.3.7 Varicella-Zoster Immune Globulin
    • 1.3.8 Others
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Hyperimmune Globulin Injection Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Government Institution
    • 1.4.3 Private Sector
    • 1.4.4 Others
  • 1.5 Global Hyperimmune Globulin Injection Market Size & Forecast
    • 1.5.1 Global Hyperimmune Globulin Injection Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Hyperimmune Globulin Injection Sales Quantity (2021-2032)
    • 1.5.3 Global Hyperimmune Globulin Injection Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 CSL Behring
    • 2.1.1 CSL Behring Details
    • 2.1.2 CSL Behring Major Business
    • 2.1.3 CSL Behring Hyperimmune Globulin Injection Product and Services
    • 2.1.4 CSL Behring Hyperimmune Globulin Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 CSL Behring Recent Developments/Updates
  • 2.2 Grifols
    • 2.2.1 Grifols Details
    • 2.2.2 Grifols Major Business
    • 2.2.3 Grifols Hyperimmune Globulin Injection Product and Services
    • 2.2.4 Grifols Hyperimmune Globulin Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Grifols Recent Developments/Updates
  • 2.3 Biotest
    • 2.3.1 Biotest Details
    • 2.3.2 Biotest Major Business
    • 2.3.3 Biotest Hyperimmune Globulin Injection Product and Services
    • 2.3.4 Biotest Hyperimmune Globulin Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Biotest Recent Developments/Updates
  • 2.4 Kedrion
    • 2.4.1 Kedrion Details
    • 2.4.2 Kedrion Major Business
    • 2.4.3 Kedrion Hyperimmune Globulin Injection Product and Services
    • 2.4.4 Kedrion Hyperimmune Globulin Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Kedrion Recent Developments/Updates
  • 2.5 Emergent
    • 2.5.1 Emergent Details
    • 2.5.2 Emergent Major Business
    • 2.5.3 Emergent Hyperimmune Globulin Injection Product and Services
    • 2.5.4 Emergent Hyperimmune Globulin Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Emergent Recent Developments/Updates
  • 2.6 Kamada
    • 2.6.1 Kamada Details
    • 2.6.2 Kamada Major Business
    • 2.6.3 Kamada Hyperimmune Globulin Injection Product and Services
    • 2.6.4 Kamada Hyperimmune Globulin Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Kamada Recent Developments/Updates
  • 2.7 CNBG
    • 2.7.1 CNBG Details
    • 2.7.2 CNBG Major Business
    • 2.7.3 CNBG Hyperimmune Globulin Injection Product and Services
    • 2.7.4 CNBG Hyperimmune Globulin Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 CNBG Recent Developments/Updates
  • 2.8 Hualan Bio
    • 2.8.1 Hualan Bio Details
    • 2.8.2 Hualan Bio Major Business
    • 2.8.3 Hualan Bio Hyperimmune Globulin Injection Product and Services
    • 2.8.4 Hualan Bio Hyperimmune Globulin Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Hualan Bio Recent Developments/Updates
  • 2.9 Shanghai RAAS
    • 2.9.1 Shanghai RAAS Details
    • 2.9.2 Shanghai RAAS Major Business
    • 2.9.3 Shanghai RAAS Hyperimmune Globulin Injection Product and Services
    • 2.9.4 Shanghai RAAS Hyperimmune Globulin Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Shanghai RAAS Recent Developments/Updates
  • 2.10 CBPO
    • 2.10.1 CBPO Details
    • 2.10.2 CBPO Major Business
    • 2.10.3 CBPO Hyperimmune Globulin Injection Product and Services
    • 2.10.4 CBPO Hyperimmune Globulin Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 CBPO Recent Developments/Updates
  • 2.11 Sichuan Yuanda Shuyang
    • 2.11.1 Sichuan Yuanda Shuyang Details
    • 2.11.2 Sichuan Yuanda Shuyang Major Business
    • 2.11.3 Sichuan Yuanda Shuyang Hyperimmune Globulin Injection Product and Services
    • 2.11.4 Sichuan Yuanda Shuyang Hyperimmune Globulin Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Sichuan Yuanda Shuyang Recent Developments/Updates
  • 2.12 ADMA Biologics
    • 2.12.1 ADMA Biologics Details
    • 2.12.2 ADMA Biologics Major Business
    • 2.12.3 ADMA Biologics Hyperimmune Globulin Injection Product and Services
    • 2.12.4 ADMA Biologics Hyperimmune Globulin Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 ADMA Biologics Recent Developments/Updates

3 Competitive Environment: Hyperimmune Globulin Injection by Manufacturer

  • 3.1 Global Hyperimmune Globulin Injection Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Hyperimmune Globulin Injection Revenue by Manufacturer (2021-2026)
  • 3.3 Global Hyperimmune Globulin Injection Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Hyperimmune Globulin Injection by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Hyperimmune Globulin Injection Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Hyperimmune Globulin Injection Manufacturer Market Share in 2025
  • 3.5 Hyperimmune Globulin Injection Market: Overall Company Footprint Analysis
    • 3.5.1 Hyperimmune Globulin Injection Market: Region Footprint
    • 3.5.2 Hyperimmune Globulin Injection Market: Company Product Type Footprint
    • 3.5.3 Hyperimmune Globulin Injection Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Hyperimmune Globulin Injection Market Size by Region
    • 4.1.1 Global Hyperimmune Globulin Injection Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Hyperimmune Globulin Injection Consumption Value by Region (2021-2032)
    • 4.1.3 Global Hyperimmune Globulin Injection Average Price by Region (2021-2032)
  • 4.2 North America Hyperimmune Globulin Injection Consumption Value (2021-2032)
  • 4.3 Europe Hyperimmune Globulin Injection Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Hyperimmune Globulin Injection Consumption Value (2021-2032)
  • 4.5 South America Hyperimmune Globulin Injection Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Hyperimmune Globulin Injection Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Hyperimmune Globulin Injection Sales Quantity by Type (2021-2032)
  • 5.2 Global Hyperimmune Globulin Injection Consumption Value by Type (2021-2032)
  • 5.3 Global Hyperimmune Globulin Injection Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Hyperimmune Globulin Injection Sales Quantity by Application (2021-2032)
  • 6.2 Global Hyperimmune Globulin Injection Consumption Value by Application (2021-2032)
  • 6.3 Global Hyperimmune Globulin Injection Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Hyperimmune Globulin Injection Sales Quantity by Type (2021-2032)
  • 7.2 North America Hyperimmune Globulin Injection Sales Quantity by Application (2021-2032)
  • 7.3 North America Hyperimmune Globulin Injection Market Size by Country
    • 7.3.1 North America Hyperimmune Globulin Injection Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Hyperimmune Globulin Injection Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Hyperimmune Globulin Injection Sales Quantity by Type (2021-2032)
  • 8.2 Europe Hyperimmune Globulin Injection Sales Quantity by Application (2021-2032)
  • 8.3 Europe Hyperimmune Globulin Injection Market Size by Country
    • 8.3.1 Europe Hyperimmune Globulin Injection Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Hyperimmune Globulin Injection Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Hyperimmune Globulin Injection Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Hyperimmune Globulin Injection Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Hyperimmune Globulin Injection Market Size by Region
    • 9.3.1 Asia-Pacific Hyperimmune Globulin Injection Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Hyperimmune Globulin Injection Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Hyperimmune Globulin Injection Sales Quantity by Type (2021-2032)
  • 10.2 South America Hyperimmune Globulin Injection Sales Quantity by Application (2021-2032)
  • 10.3 South America Hyperimmune Globulin Injection Market Size by Country
    • 10.3.1 South America Hyperimmune Globulin Injection Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Hyperimmune Globulin Injection Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Hyperimmune Globulin Injection Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Hyperimmune Globulin Injection Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Hyperimmune Globulin Injection Market Size by Country
    • 11.3.1 Middle East & Africa Hyperimmune Globulin Injection Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Hyperimmune Globulin Injection Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Hyperimmune Globulin Injection Market Drivers
  • 12.2 Hyperimmune Globulin Injection Market Restraints
  • 12.3 Hyperimmune Globulin Injection Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Hyperimmune Globulin Injection and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Hyperimmune Globulin Injection
  • 13.3 Hyperimmune Globulin Injection Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Hyperimmune Globulin Injection Typical Distributors
  • 14.3 Hyperimmune Globulin Injection Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Hyperimmune Globulin Injection market size was valued at US$ 2402 million in 2025 and is forecast to a readjusted size of US$ 3659 million by 2032 with a CAGR of 6.3% during review period.
    Hyperimmune Globulin is a highly concentrated immunoglobulin containing high levels of specific antibodies used for passive immunotherapy. It is usually extracted from the plasma of recovered patients who have been infected with a specific pathogen, so these people have produced high levels of antibodies against the pathogen.
    Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
    The human plasma-based hyperimmune preparation market is driven by the increasing demand for effective treatments against specific infectious diseases and other medical conditions. Hyperimmune preparations are derived from the plasma of individuals who have recovered from a particular infection or have been vaccinated against a specific pathogen. These preparations contain high levels of antibodies targeting the specific pathogen or antigen, making them valuable for passive immunization in individuals at risk or currently affected by the same disease. The growing prevalence of infectious diseases, such as COVID-19, and the need for rapid and targeted therapeutic solutions have fueled market growth. Moreover, advancements in plasma fractionation and purification technologies have improved the production and safety of hyperimmune preparations. However, the market also faces challenges, including the complexity of large-scale plasma collection and processing, ensuring consistent antibody levels in the preparations, and maintaining a robust supply chain to meet demand during disease outbreaks or pandemics. Additionally, regulatory considerations and the need for stringent safety and quality standards are crucial challenges for manufacturers. To succeed in this market, companies must focus on research and development to expand the applications of hyperimmune preparations, collaborate with healthcare authorities and organizations to establish guidelines and protocols, and work towards enhancing plasma collection infrastructure to ensure a steady supply of human plasma-based hyperimmune preparations for critical therapeutic interventions.
    This report is a detailed and comprehensive analysis for global Hyperimmune Globulin Injection market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Hyperimmune Globulin Injection market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Hyperimmune Globulin Injection market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Hyperimmune Globulin Injection market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Hyperimmune Globulin Injection market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Hyperimmune Globulin Injection
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Hyperimmune Globulin Injection market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include CSL Behring, Grifols, Biotest, Kedrion, Emergent, Kamada, CNBG, Hualan Bio, Shanghai RAAS, CBPO, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Hyperimmune Globulin Injection market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Hepatitis B Immuneglobulins
    Rabies Immuneglobulins
    Tetanus Toxin Immuneglobulins
    Rho(D) Immune Globulin
    Cytomegalovirus Immune Globulin
    Varicella-Zoster Immune Globulin
    Others
    Market segment by Application
    Government Institution
    Private Sector
    Others
    Major players covered
    CSL Behring
    Grifols
    Biotest
    Kedrion
    Emergent
    Kamada
    CNBG
    Hualan Bio
    Shanghai RAAS
    CBPO
    Sichuan Yuanda Shuyang
    ADMA Biologics
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Hyperimmune Globulin Injection product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Hyperimmune Globulin Injection, with price, sales quantity, revenue, and global market share of Hyperimmune Globulin Injection from 2021 to 2026.
    Chapter 3, the Hyperimmune Globulin Injection competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Hyperimmune Globulin Injection breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Hyperimmune Globulin Injection market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Hyperimmune Globulin Injection.
    Chapter 14 and 15, to describe Hyperimmune Globulin Injection sales channel, distributors, customers, research findings and conclusion.

    Buy now